Veradermics to discuss Phase 2/3 VDPHL01 topline results on April 27, 2026
Veradermics will host an April 27, 2026 investor call to review topline results from Part A of its Phase 2/3 '302' trial of VDPHL01 in males with pattern hair loss. VDPHL01 is an investigational extended-release oral minoxidil tablet in Phase 3 development.
Veradermics, Incorporated announced it will host an investor call and live webcast to review topline results from Part A of its randomized, double-blind, placebo-controlled Phase 2/3 '302' clinical trial evaluating VDPHL01 in males with mild-to-moderate pattern hair loss. The conference call will take place on Monday, April 27, 2026 at 8:00 a.m. ET.
The event and the accompanying slides will be available on the Events page in the Investors section of the company’s website. A replay will be available following the call.
VDPHL01, an extended-release minoxidil tablet, is a proprietary investigational, orally available non-hormonal drug in Phase 3 development for pattern hair loss in both women and men. The proprietary extended-release formulation utilizes a gel matrix designed to deliver long-lasting, steady release of minoxidil for sustained absorption. The company said VDPHL01 has been shown to avoid the high peak concentrations of immediate-release oral minoxidil, while extending time above the minimum hair growth threshold to increase time for hair to grow.
If approved, VDPHL01 would be the only FDA-approved oral non-hormonal treatment for pattern hair loss in both male and female patients. VDPHL01 is protected by a broad library of patents and patent applications related to the key innovations of VDPHL01, and the earliest expiring patent term is 2043.
Pattern hair loss, also known as androgenetic alopecia, affects an estimated 80 million people in the United States, including 30 million women and 50 million men. There have been no new FDA-approved prescription medicines for pattern hair loss in nearly 30 years, according to the company.